Related Experiment Video
Updated: Feb 17, 2026

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing
Published on: January 22, 2019
BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency
Panpan Lu1, Yinzhong Shen2, He Yang1
1State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, 200438, China.
Abstract:
Persistent latent reservoir in resting CD4+ T cells is a major obstacle in curing HIV-1 infection. Effective strategies for eradication of the HIV-1 reservoir are urgently needed. We report here for the first time that two BET inhibitors, RVX-208, which has entered phase II clinical trials for diverse cardiovascular disorders, and PFI-1, which has been widely studied in oncology, can reactivate HIV-1 from latency. RVX-208 and PFI-1 treatment alone or in combination with other latency reversing agents efficiently reactivated HIV-1 transcription through an up-regulation of P-TEFb by increasing CDK9 Thr-186 phosphorylation in latently infected Jurkat T cells in vitro. The two BET inhibitors also reactivated HIV-1 transcription in cART treated patient-derived resting CD4+ T cells ex vivo, without influence on global immune cell activation. Our findings, in combination with previous reports, further confirm that BET inhibitors are a group of leading compounds for combating HIV-1 latency for viral eradication.
Insights
Two BET inhibitors, RVX-208 and PFI-1, effectively reactivate latent HIV-1 (Human Immunodeficiency Virus type 1) by up-regulating P-TEFb. This finding offers a promising strategy for HIV-1 reservoir eradication.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- The persistent latent reservoir in resting CD4+ T cells is a significant barrier to curing HIV-1 infection.
- Developing effective strategies for HIV-1 reservoir eradication is a critical research priority.
Purpose of the Study:
- To investigate the potential of BET inhibitors, RVX-208 and PFI-1, in reactivating latent HIV-1.
- To explore the mechanism by which these BET inhibitors reverse HIV-1 latency.
Main Methods:
- Treatment of latently infected Jurkat T cells and ex vivo patient-derived resting CD4+ T cells with BET inhibitors RVX-208 and PFI-1.
- Assessment of HIV-1 transcription reactivation and P-TEFb pathway modulation, including CDK9 Thr-186 phosphorylation.
- Evaluation of global immune cell activation.
Main Results:
- RVX-208 and PFI-1 demonstrated the ability to reactivate HIV-1 transcription from latency, both individually and in combination with other latency-reversing agents.
- The reactivation mechanism involves up-regulation of P-TEFb via increased CDK9 Thr-186 phosphorylation.
- HIV-1 reactivation was observed in ex vivo settings using patient-derived cells without inducing global immune cell activation.
Conclusions:
- BET inhibitors RVX-208 and PFI-1 are effective in reactivating latent HIV-1.
- These compounds represent a promising therapeutic avenue for targeting the HIV-1 reservoir and achieving viral eradication.
More Related Videos
07:22A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
Published on: August 14, 2018
09:38Identification of Nucleolar Factors During HIV-1 Replication Through Rev Immunoprecipitation and Mass Spectrometry
Published on: June 26, 2019
Related Concept Videos
Size and Structure of Viral Genomes
Retrovirus Life Cycles
Retroviruses